Related Experiment Video
Updated: Jul 3, 2026
08:23
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia
Pinar Ulug1, Nisha Vasavda, Rohan Kumar
1King's College London School of Medicine, Division of Gene and Cell Based Therapy, Denmark Hill Campus, London SE5 9NU.
American Journal of Hematology
|July 11, 2008
Summary
Hydroxyurea therapy significantly lowered cell-free DNA (cfDNA) levels in sickle cell disease (SCD) patients. This suggests cfDNA may serve as a biomarker for monitoring hydroxyurea treatment effectiveness in SCD.
Area of Science:
- Hematology
- Molecular Biology
Background:
- Sickle cell disease (SCD) is a genetic blood disorder characterized by acute pain crises.
- Hydroxyurea is a standard treatment for SCD, primarily used to reduce pain frequency.
Purpose of the Study:
- To investigate the impact of hydroxyurea therapy on cell-free DNA (cfDNA) levels in patients with SCD.
- To explore cfDNA as a potential biomarker for hydroxyurea treatment response in SCD.
Main Methods:
- Prospective study involving 10 adult SCD patients initiating hydroxyurea therapy.
- Measurement of cfDNA levels before and after hydroxyurea treatment.
- Comparison of cfDNA levels in treated patients versus a control group of 115 SCD patients who never received hydroxyurea.
Main Results:
- A significant reduction in mean cfDNA levels was observed in all 10 patients after hydroxyurea treatment (1,879 GE/mL to 780 GE/mL, P = 0.002).
- Pre-treatment cfDNA levels in the study group were significantly higher than in the control group (1,879 vs 975 GE/mL, P = 0.02).
Conclusions:
- Hydroxyurea therapy leads to a significant decrease in cfDNA levels in SCD patients.
- cfDNA levels show potential as a monitoring tool for hydroxyurea therapy response in sickle cell disease.
Related Concept Videos
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:14Erythropoiesis
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...